SpudCell marks a milestone for synthetic biology, but it is not fully alive. It will, however, help scientists answer key ...
The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said. Merck KGaA has agreed to buy Bio-Techne for $11.3 billion ...
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential treatment of multiple myeloma.
CHICAGO & MILPITAS, Calif.--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results